опухольанемияэритропэтинвыживаемостьтромбозы1.1. Ludwig H., van Bells S., Barret-Lee P. et al The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293—306.Ludwig H., van Bells S., Barret-Lee P. et al The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293—306.2.2. Cella D.The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 Suppl 2): 13—9.Cella D.The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 Suppl 2): 13—9.3.3. Lefebvre P., Vecerman F., Sarokham B. et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin Cur Med Res Opin 2006;22:1929—37.Lefebvre P., Vecerman F., Sarokham B. et al. Relationship between hemoglobin level and quality of life in anemic patients with chronic kidney disease receiving epoetin Cur Med Res Opin 2006;22:1929—37.4.4. Glaspy J., Bukowski R., Steinberg D. et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group J Clin Oncol 1997;15:1218—34.Glaspy J., Bukowski R., Steinberg D. et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group J Clin Oncol 1997;15:1218—34.5.5. Teicher B.A., Abrams M.J., Rosbe K.W. et al. Cytotoxicity, radiosensitization, antitumor activity, and interaction with hyperthermia of a Co(III) mustard complex. Cancer Res 1990;50:6971—5.Teicher B.A., Abrams M.J., Rosbe K.W. et al. Cytotoxicity, radiosensitization, antitumor activity, and interaction with hyperthermia of a Co(III) mustard complex. Cancer Res 1990;50:6971—5.6.6. Brizel D.M., Sibley G.S., Prosnitz L.R. et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285—9.Brizel D.M., Sibley G.S., Prosnitz L.R. et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285—9.7.7. Bunn H.F., Poyton R.O. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996;76(3):839—85.Bunn H.F., Poyton R.O. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996;76(3):839—85.8.8. Larcher F., Murillas R., Bolontrade M. et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998;17:303—11.Larcher F., Murillas R., Bolontrade M. et al. VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development. Oncogene 1998;17:303—11.9.9. Huang L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxiainducible factor 1a is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987—92.Huang L.E., Gu J., Schau M., Bunn H.F. Regulation of hypoxiainducible factor 1a is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95:7987—92.10.10. Graeber T.G., Osmanian C., Jacks T. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379(6560): 88—91.Graeber T.G., Osmanian C., Jacks T. et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 1996;379(6560): 88—91.11.11. Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214—21.Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001;91:2214—21.12.12. Johnson J.Y., Waddelow T.A., Caro J. et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989;74:130—8.Johnson J.Y., Waddelow T.A., Caro J. et al. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice. Blood 1989;74:130—8.13.13. DeRienzo D.P., Saleem A. Anemia of chronic disease: a review of pathogenesis. Tex Med 1990;86:80—3.DeRienzo D.P., Saleem A. Anemia of chronic disease: a review of pathogenesis. Tex Med 1990;86:80—3.14.14. Moldawer L.L., Marano M.A., Wei H. et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989;3:1637—43.Moldawer L.L., Marano M.A., Wei H. et al. Cachectin/tumor necrosis factor-alpha alters red blood cell kinetics and induces anemia in vivo. FASEB J 1989;3:1637—43.15.15. Weinstein D.A., Roy C.N., Fleming M.D. et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002;100:3776—81.Weinstein D.A., Roy C.N., Fleming M.D. et al. Inappropriate expression of hepcidin is associated with iron refractory anemia: implications for the anemia of chronic disease. Blood 2002;100:3776—81.16.16. Nemeth E., Tuttle M.S., Powelson J. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090—3.Nemeth E., Tuttle M.S., Powelson J. et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090—3.17.17. Detivaud L., Nemeth E., Boudjema K. et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746—8.Detivaud L., Nemeth E., Boudjema K. et al. Hepcidin levels in humans are correlated with hepatic iron stores, hemoglobin levels, and hepatic function. Blood 2005;106:746—8.18.18. Miller C.B., Jones R.J., Piantadosi S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689—92.Miller C.B., Jones R.J., Piantadosi S. et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med 1990;322:1689—92.19.19. Blajchman M.A., Vamvakas E.C. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006;355(13):1303—5.Blajchman M.A., Vamvakas E.C. The continuing risk of transfusion-transmitted infections. N Engl J Med 2006;355(13):1303—5.20.20. Goodnough L.T., Monk T.G., Andriole G.L. Erythropoietin therapy. N Engl J Med 1997;336:933—8.Goodnough L.T., Monk T.G., Andriole G.L. Erythropoietin therapy. N Engl J Med 1997;336:933—8.21.21. Bokemeyer C., Aapro M.S., Courdi A. et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258—70.Bokemeyer C., Aapro M.S., Courdi A. et al. EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258—70.22.22. van der Meer P., Lipcic E., Henning R.H. et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125—33.van der Meer P., Lipcic E., Henning R.H. et al. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction. J Am Coll Cardiol 2005;46:125—33.23.23. Acs G., Acs P., Beckwith S.M. et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561—5.Acs G., Acs P., Beckwith S.M. et al. Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 2001;61:3561—5.24.24. Anagnostou A., Liu Z., Steiner M. et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974—8.Anagnostou A., Liu Z., Steiner M. et al. Erythropoietin receptor mRNA expression in human endothelial cells. Proc Natl Acad Sci USA 1994;91:3974—8.25.25. Westenfelder C., Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647—57.Westenfelder C., Baranowski R.L. Erythropoietin stimulates proliferation of human renal carcinoma cells. Kidney Int 2000;58:647—57.26.26. Sinclair A., Busse L., Arnold G. et al. Epo receptor transcription is not elevated nor predictive of surface expression in human tumor cells. Proc Assoc Cancer Res 2005;46: abstr 5457.Sinclair A., Busse L., Arnold G. et al. Epo receptor transcription is not elevated nor predictive of surface expression in human tumor cells. Proc Assoc Cancer Res 2005;46: abstr 5457.27.27. Busse L., Sinclair A., Rogers N. et al. Is Epo receptor over expressed in human tumor cells. Proc Am Assoc Cancer Res 2005;46: abstr 4562.Busse L., Sinclair A., Rogers N. et al. Is Epo receptor over expressed in human tumor cells. Proc Am Assoc Cancer Res 2005;46: abstr 4562.28.28. Gewirtz D.A., Walker T.D., Di X. et al. Influence of erythropoietin on sensitivity to chemotherapeutic drugs in breast and leukemic tumor cells; implications for erythropoietin use in cancer patients Proc Amer Assoc Cancer Res 2005; 46: abstr 41157.Gewirtz D.A., Walker T.D., Di X. et al. Influence of erythropoietin on sensitivity to chemotherapeutic drugs in breast and leukemic tumor cells; implications for erythropoietin use in cancer patients Proc Amer Assoc Cancer Res 2005; 46: abstr 41157.29.29. Thaws O., Kelleher D.K., Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.Cancer Res 2001;61:1358—61.Thaws O., Kelleher D.K., Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors.Cancer Res 2001;61:1358—61.30.30. Carvalho G., Lefaucheur C., Cherbonier C. et al. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 2005;24:737—45.Carvalho G., Lefaucheur C., Cherbonier C. et al. Chemosensitization by erythropoietin through inhibition of the NF-kappaB rescue pathway. Oncogene 2005;24:737—45.31.31. Littlewood T.J., Bajetta E., Nortier J.W. et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19: 2865—74.Littlewood T.J., Bajetta E., Nortier J.W. et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19: 2865—74.32.32. Leyland-Jones B.; Best Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4(8):459—60.Leyland-Jones B.; Best Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4(8):459—60.33.33. Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255—60.Henke M., Laszig R., Rube C. et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255—60.34.34. Bolhius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated metaanalysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708—14.Bolhius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: updated metaanalysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006;98:708—14.35.35. Aapro M., Coffier B., Dunst J. et al. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br J Cancer 2006;95:1467—73.Aapro M., Coffier B., Dunst J. et al. Effect of treatment with epoetin beta on short-term tumour progression and survival in anaemic patients with cancer: A meta-analysis. Br J Cancer 2006;95:1467—73.36.36. Boogaerts M., Oberhoff C., Ten Bockel-Huinink W. et al. Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a metaanalysis. Antnticancer Res 2006 26: 479—84.Boogaerts M., Oberhoff C., Ten Bockel-Huinink W. et al. Epoetin beta (NeoRecormon) therapy in patients with solid tumours receiving platinum and non-platinum chemotherapy: a metaanalysis. Antnticancer Res 2006 26: 479—84.37.37. Aapro M., Barnadas A., Leonard R.C. et al. Effects of epoietin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of BRAVE trial. 29th San Antonio Breast Cancer Symposium. Abstr 6079.Aapro M., Barnadas A., Leonard R.C. et al. Effects of epoietin beta treatment in patients with metastatic breast cancer receiving chemotherapy. Results of BRAVE trial. 29th San Antonio Breast Cancer Symposium. Abstr 6079.38.38. Wun T., Law L., Harvey D. et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514—20.Wun T., Law L., Harvey D. et al. Increased incidence of symptomatic venous thrombosis in patients with cervical carcinoma treated with concurrent chemotherapy, radiation, and erythropoietin. Cancer 2003;98:1514—20.39.39. Galli M., Elice F., Crippa C. et al. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004;89(9): 1141—2.Galli M., Elice F., Crippa C. et al. Recombinant human erythropoietin and the risk of thrombosis in patients receiving thalidomide for multiple myeloma. Haematologica 2004;89(9): 1141—2.40.40. Besarab A., Bolton W.K., Browne J.K. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339(9): 584—90.Besarab A., Bolton W.K., Browne J.K. et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998;339(9): 584—90.41.41. Valles J., Santos M.T., Aznar J. et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood 2002;99:3978—84.Valles J., Santos M.T., Aznar J. et al. Platelet-erythrocyte interactions enhance alpha(IIb)beta(3) integrin receptor activation and P-selectin expression during platelet recruitment: down-regulation by aspirin ex vivo. Blood 2002;99:3978—84.42.42. Stohlawetz P.J., Drzilo L., Hergovitch N. et al. Effects of erythropoietin on platelet reactivity and throm-bopoiesis in humans. Blood 2000;95:2983—9.Stohlawetz P.J., Drzilo L., Hergovitch N. et al. Effects of erythropoietin on platelet reactivity and throm-bopoiesis in humans. Blood 2000;95:2983—9.43.43. Cazzola M., Beguin E., Kloczko J. et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122: 386—93.Cazzola M., Beguin E., Kloczko J. et al. Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. Br J Haematol 2003;122: 386—93.44.44. Canon J.L., Vansteenkiste J., Bodoky G. et al. Randomized, doubleblind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273—84.Canon J.L., Vansteenkiste J., Bodoky G. et al. Randomized, doubleblind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. J Natl Cancer Inst 2006;98:273—84.45.45. Pawlicki M., Jassem J., Bosze P. et al. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs 1997;8: 949—57.Pawlicki M., Jassem J., Bosze P. et al. A multicenter study of recombinant human erythropoietin (epoetin alpha) in the management of anemia in cancer patients receiving chemotherapy. Anticancer Drugs 1997;8: 949—57.46.46. Auerbach M., Ballard H., Trout J.R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301—7.Auerbach M., Ballard H., Trout J.R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301—7.47.47. Henry D.H., Dahl N.V., Auerbach M. et al. Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy - results of a multicenter, randomized trial. Blood 2004;104: abstr 3696.Henry D.H., Dahl N.V., Auerbach M. et al. Intravenous ferric gluconate (FG) for increasing response to epoetin (EPO) in patients with anemia of cancer chemotherapy - results of a multicenter, randomized trial. Blood 2004;104: abstr 3696.